Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)

Gan & Lee Pharmaceuticals to Present Positive Data from Two Clinical Studies of GZR4, a Once-weekly Insulin, at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)

Gan & Lee’s Insulin Glargine U300 Clinical Research Findings Published in Frontiers in Endocrinology

Gan & Lee Teams Up with Algerian Pharmaceutical Company to Pioneer New Horizons in African Market

Gan & Lee Pharmaceuticals’ Bi-weekly（twice a month） GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial

Gan & Lee Pharmaceuticals Successfully Shines at the American Diabetes Association's 84th Scientific Sessions